10-K: Regeneron's 2025 Performance: Dupixent Drives Growth Amid EYLEA Decline

Regeneron Pharmaceuticals reports increased net income and diluted EPS in 2025, driven by strong Dupixent sales, despite a significant decline in U.S. EYLEA revenue and ongoing regulatory and legal challenges.

Summary

• Total revenues increased to $14,342.9 million in 2025 from $14,202.0 million in 2024.
• Net income rose to $4,504.9 million in 2025 from $4,412.6 million in 2024.
• Diluted net income per share increased to $41.48 in 2025 from $38.34 in 2024.
• U.S. net product sales of EYLEA HD grew to $1,636.9 million in 2025 from $1,201.1 million in 2024.
• U.S. net product sales of EYLEA declined significantly by 42% to $2,747.8 million in 2025 from $4,767.1 million in 2024, primarily due to biosimilar competition and patient transition to EYLEA HD.
• Total U.S. EYLEA HD and EYLEA net product sales decreased to $4,384.7 million in 2025 from $5,968.2 million in 2024.
• Global net product sales of Libtayo increased to $1,452.2 million in 2025 from $1,216.8 million in 2024.
• Regeneron's share of profits from the Sanofi collaboration (primarily Dupixent) increased to $5,241.6 million in 2025 from $3,923.5 million in 2024.
• Research and development expenses increased to $5,850.2 million in 2025 from $5,132.0 million in 2024.
• Selling, general, and administrative expenses decreased to $2,700.0 million in 2025 from $2,954.4 million in 2024, partly due to lower charitable contributions.
• Gross margin on net product sales decreased to 82% in 2025 from 86% in 2024.
• The company initiated a quarterly cash dividend program in 2025, declaring $0.88 per share, and increased it to $0.94 per share in January 2026.
• FDA issued Complete Response Letters (CRLs) for EYLEA HD pre-filled syringe and Ordspono BLA due to unresolved inspection findings at third-party manufacturer Catalent.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report. While overall revenue and net income grew, driven by Dupixent and EYLEA HD, the significant decline in core EYLEA sales due to biosimilar competition and regulatory delays for key product candidates (EYLEA HD pre-filled syringe, Ordspono) present notable headwinds and uncertainties.

Positives

• Overall revenue, net income, and diluted EPS increased year-over-year.
• Strong growth in U.S. EYLEA HD sales, reaching $1,636.9 million in 2025.
• Significant growth in Dupixent sales (Sanofi collaboration), with Regeneron's share of profits increasing to $5,241.6 million.
• Libtayo global net product sales continued to grow, reaching $1,452.2 million.
• Successful Phase 3 trial for Garetosmab in FOP, with regulatory decisions expected in H2 2026.
• Positive Phase 3 trial results for Cemdisiran in myasthenia gravis, with NDA submission expected in Q1 2026.
• Lynozyfic received FDA and EC approval for relapsed/refractory multiple myeloma.
• DB-OTO received FDA Commissioner's National Priority Voucher, with BLA decision expected in H1 2026.
• Jury verdict in Regeneron's favor in the Praluent antitrust lawsuit against Amgen, awarding $135.6 million in compensatory damages and $271.2 million in punitive damages.
• Initiated a quarterly cash dividend program in 2025 and increased the dividend to $0.94 per share in January 2026.
• Strong employee retention rate of nearly 93% in 2025 and high employee engagement.

Negatives

• U.S. EYLEA net product sales declined significantly by 42% in 2025 due to biosimilar competition and patient transition to EYLEA HD.
• Total U.S. EYLEA HD and EYLEA net product sales decreased in 2025.
• FDA issued Complete Response Letters (CRLs) for EYLEA HD pre-filled syringe and Ordspono BLA due to unresolved inspection findings at third-party manufacturer Catalent.
• One of two Phase 3 trials for Itepekimab in COPD (AERIFY-2) did not meet its primary endpoint.
• Phase 3 ATTR-CM trial for Nex-z is on FDA clinical hold.
• Gross margin on net product sales decreased to 82% in 2025, partly due to ongoing manufacturing investments and higher inventory write-offs and reserves.
• Ongoing patent litigation for EYLEA in multiple jurisdictions, with some adverse rulings (e.g., EPO revocation of '306 Patent, South Korean IP High Court invalidating '811 Patent).
• Ongoing civil proceedings by the U.S. Department of Justice and other payors alleging Anti-Kickback Statute and False Claims Act violations.
• Shareholder derivative complaints and a class action civil complaint related to the DOJ matters and EYLEA HD launch.
• Regeneron's share of profits from the Bayer collaboration (EYLEA outside U.S.) decreased in 2025.

Risks

• Substantial dependence on the commercial success of EYLEA HD, EYLEA, and Dupixent.
• Significant competition for marketed products, including biosimilars for EYLEA, which has already led to a 42% decline in U.S. EYLEA sales in 2025.
• Uncertainty of market acceptance and commercial success of new products and indications.
• Drug development is costly, time-consuming, and highly uncertain; clinical trials may yield unfavorable results or be delayed.
• Serious complications or side effects from products or product candidates could lead to regulatory approval revocation or development discontinuation.
• Inability to formulate or manufacture product candidates suitable for clinical or commercial use could delay or prevent development/approval.
• Reliance on drug-delivery devices (e.g., pre-filled syringes) introduces additional regulatory and commercialization risks, as evidenced by the EYLEA HD pre-filled syringe CRL.
• Inability to protect trade secrets or insufficient patent protection could harm competitive position.
• Risk of infringing on patents or proprietary rights of others, leading to litigation and damages.
• Loss or limitation of patent rights and regulatory pathways for biosimilar competition could reduce market exclusivity.
• Reliance on limited internal and contracted manufacturing and supply chain capacity, with risks of disruptions, failures, and non-compliance with cGMP.
• Costs related to excess inventory or unused manufacturing capacity if product sales do not meet expectations or launches are delayed/unsuccessful.
• Product liability claims if products harm people or are perceived to harm them.
• Challenges under U.S. federal/state and foreign healthcare fraud and abuse laws, leading to civil/criminal proceedings or penalties.
• Failure to comply with reporting and payment obligations under government pricing programs (Medicaid, 340B, Medicare) could lead to penalties and fines.
• Risks from improper conduct of employees, agents, contractors, or collaborators (e.g., FCPA, U.K. Bribery Act violations).
• Changes in laws, regulations, and policies affecting the healthcare industry (e.g., drug price control measures, Inflation Reduction Act provisions).
• Risks associated with international operations, including unfamiliar laws, political/economic instability, currency fluctuations, tariffs, and trade restrictions.
• Risks related to personal data collection, processing, and sharing, including compliance with GDPR and state privacy laws.
• Risks related to increasing use of AI-based solutions, including data security, privacy, and unintended biases.
• Dependence on key personnel, with intense competition for qualified scientists and managerial staff.
• Significant disruptions of information technology systems or data security breaches.
• Public health outbreaks, epidemics, or pandemics could adversely affect business.
• Indebtedness could limit access to capital and flexibility.
• Stock price volatility due to various factors, including biosimilar launches and litigation outcomes.
• Existing shareholders (Class A stock) can exert substantial influence over matters requiring shareholder approval.
• Anti-takeover provisions in charter, by-laws, and New York corporate law.

Future Outlook

The company expects to continue incurring substantial expenses related to its research and development activities, which are anticipated to expand and require additional resources. Significant capital expenditures are projected over the next several years for facility expansion. The timing and success of new product approvals and commercialization remain uncertain. The company intends to continue paying quarterly cash dividends, subject to board authorization and financial factors.

Management Comments

• Our ability to generate profits and to generate positive cash flow from operations over the next several years depends significantly on the success in commercializing our products, including EYLEA HD and Dupixent.

Industry Context

StockSavvy.ai notes that the pharmaceutical and biotechnology industries are highly competitive, with increasing pressure from biosimilars and drug pricing regulations. The significant decline in EYLEA sales due to biosimilar competition highlights a major industry trend impacting innovator products. The company's strategic collaborations (Sanofi, Bayer, Alnylam, Intellia, Hansoh, Tessera) are a common industry approach to share risks and leverage expertise in drug discovery, development, and commercialization. The increasing use of AI-based solutions reflects a broader industry trend towards technological innovation in drug discovery and operations.

Comparison to Industry Standards

• EYLEA HD and EYLEA compete with other VEGF inhibitors like Genentech/Roche's Vabysmo, Avastin (off-label), Novartis/Genentech/Roche's Lucentis, Novartis' Beovu, and biosimilars such as Amgen's Pavblu, Sandoz's Afqlir, Sam Chun Dang's Eiyzey, Samsung Bioepis' Byooviz, Xbrane/STADA's Ximluci, and Formycon/Bioeq/Sandoz/Teva's Cimerli.
• Dupixent faces competition in atopic dermatitis from Almirall/Eli Lilly's Ebglyss, AbbVie's Rinvoq, Galderma/Maruho/Chugai's Nemluvio/Mitchga, LEO Pharma's Adbry/Adtralza, and Pfizer's Cibinqo. In asthma, it competes with AstraZeneca/Amgen's Tezspire, AstraZeneca's Fasenra, GSK's Nucala and Exdensur, Roche/Novartis' Xolair, and Celltrion's Omlyclo.
• Libtayo competes with other PD-1/PDL-1 inhibitors like Merck's Keytruda, Bristol-Myers Squibb's Opdivo, Roche's Tecentriq, AstraZeneca's Imfinzi, Pfizer/Merck KGaA's Bavencio, and Checkpoint Therapeutics' Unloxcyt.
• Lynozyfic faces competition from other bispecific antibodies and CAR-T cell therapies targeting BCMA, GPRC5D, and other targets for relapsed/refractory multiple myeloma.
• Praluent, Evkeeza, and Kevzara face competition from antibodies or other molecules (siRNAs, oral small molecules) targeting PCSK9, ANGPTL3, and IL-6/IL-6R, respectively.

Management Changes

Corporate Governance

Legal Proceedings

• **EYLEA Patent Litigation (U.S.)**: Settlements with Mylan/Biocon, Celltrion, Formycon, and Sandoz preclude their biosimilar launches until H2 2026. An ongoing patent infringement lawsuit against Amgen includes Amgen's allegations of fraud and antitrust violations. USPTO denied IPR petitions against the '865 and '345 Patents.
• **EYLEA Patent Litigation (Outside U.S.)**: Settlements with Biocon, Celltrion, Alvotech, and Samsung Bioepis allow ex-US launches in 2026. The EPO revoked the '306 Patent (appealed by Regeneron). German courts upheld the '691 Patent and granted injunctions against Formycon, Alvotech, Celltrion, and Sandoz. A Dutch court upheld the '691 and '306 Patents and granted an injunction against Samsung Bioepis. An Australian court denied a preliminary injunction against Sandoz. The South Korean IP High Court invalidated the '811 Patent (appealed by Regeneron).
• **EYLEA HD Pre-filled Syringe Antitrust Lawsuit**: Against Novartis, alleging Sherman Antitrust Act violations and tortious interference. The Second Circuit reversed the District Court's dismissal and remanded for further proceedings.
• **Praluent Antitrust Lawsuit**: Against Amgen, alleging anticompetitive bundling. A jury awarded Regeneron $135.6 million in compensatory damages and $271.2 million in punitive damages. Post-trial motions are pending.
• **DOJ Matters**: Civil complaints initiated or joined by the U.S. Department of Justice and U.S. Attorney's Office for the District of Massachusetts allege violations of the federal Anti-Kickback Statute and False Claims Act related to patient assistance organizations and EYLEA reimbursement rates. These investigations and litigations are ongoing.
• **Other Payor Lawsuits**: Several lawsuits by UnitedHealthcare, Humana, Blue Cross Blue Shield, Medical Mutual of Ohio, Horizon Healthcare Services, and Local 464A allege state law and RICO violations related to the conduct in the DOJ June 2020 Civil Complaint. Most of these lawsuits are stayed. A new putative class action complaint filed by Medicare Advantage plans in June 2024 was transferred to the U.S. District Court for the District of Massachusetts and subsequently stayed.
• **Shareholder Derivative Complaints**: Multiple complaints allege breach of fiduciary duties by directors and executive officers related to the DOJ matters and director compensation.
• **Class Action Civil Complaint**: A putative class action alleges federal securities law violations in connection with statements or disclosures purportedly related to the DOJ matters and the launch of EYLEA HD.
• **Sanofi Litigation**: Regeneron filed a lawsuit against Sanofi and certain affiliated entities alleging breach of the collaboration agreement concerning Sanofi's obligation to provide full access to material information relating to commercialization and Regeneron's audit rights.

Related Party Transactions

• Collaboration agreements with Sanofi and Bayer involve profit sharing and reimbursement of development expenses. As of December 31, 2025, the contingent reimbursement obligation to Sanofi was approximately $595 million, and to Bayer was approximately $296 million.
• The Amended and Restated Investor Agreement with Sanofi includes 'standstill' provisions contractually prohibiting Sanofi from seeking to exert control or acquire more than 30% of Regeneron's Class A and Common Stock.

Stakeholder Impact

• **Shareholders**: Impacted by stock price volatility, dividend payments, share repurchase programs, and outcomes of litigation and clinical trials. Holders of Class A Stock have greater voting power.
• **Employees**: Dependent on the company's ability to attract and retain talent, with competitive compensation, benefits, and development opportunities. Stock-based compensation is a significant part of their pay.
• **Customers (Healthcare Providers, Distributors, Pharmacies)**: Affected by product availability, pricing, reimbursement policies, and competition.
• **Patients**: Directly impacted by the availability, safety, and efficacy of current and future medicines.
• **Collaborators (Sanofi, Bayer, Alnylam, Intellia, Hansoh, Tessera)**: Their financial results and strategic direction are intertwined with Regeneron's success and the terms of their agreements.
• **Creditors**: Impacted by the company's overall financial health and ability to manage its indebtedness.

Next Steps

• FDA decision for EYLEA HD pre-filled syringe expected in Q2 2026.
• EC decision on regulatory submission for Dupixent in bullous pemphigoid expected in H1 2026.
• FDA decision on sBLA for Dupixent in AFRS expected in February 2026.
• Initiate second Phase 3 study in cat allergy (REGN1908-1909) in H1 2026.
• Report results from Phase 3 study versus pembrolizumab in first-line metastatic melanoma (Fianlimab) in H1 2026.
• Report Phase 2 data in first-line advanced NSCLC (Fianlimab) in H1 2026.
• Report initial results from lead-in cohort of Phase 3 study in geographic atrophy (Pozelimab + cemdisiran) in H2 2026.
• NDA submission for Cemdisiran in myasthenia gravis expected in Q1 2026.
• Initiate additional Phase 3 studies in anticoagulation (REGN7508, REGN9933) in H1 2026.
• FDA decision on BLA and EC decision on MAA for Garetosmab in FOP expected in H2 2026.
• FDA decision on BLA for DB-OTO expected in H1 2026.
• Initiate additional Phase 3 studies in multiple myeloma and precursor conditions (Lynozyfic) in 2026.
• Report results from Phase 3 study in PNH (Pozelimab + cemdisiran) in Q4 2026/Q1 2027.
• Staggered board of directors will be phased out beginning in 2026, with annual election of all directors commencing with the 2028 annual meeting.
• Company expects to incur capital expenditures of $1.100 billion to $1.300 billion in 2026 for facility expansion.
• Company committed to matching donations for up to a total of $200 million during 2026 for the Retinal Vascular and Neovascular Disease Fund.

Key Dates

Recommendation

Regeneron demonstrates strong growth in key products like Dupixent and EYLEA HD, driving overall revenue and net income increases. However, the significant decline in EYLEA sales due to biosimilar competition and multiple regulatory setbacks for pipeline assets (EYLEA HD pre-filled syringe, Ordspono, Nex-z) introduce considerable uncertainty. The ongoing extensive legal proceedings, particularly the DOJ investigations and patent litigations, represent material contingent liabilities and reputational risks. While the Praluent antitrust win is positive, the overall picture is mixed, suggesting a 'hold' recommendation until there is greater clarity on the impact of biosimilar erosion, resolution of regulatory hurdles, and the outcomes of the various legal challenges.

Keywords

Biotechnology, Pharmaceuticals, Regeneron, EYLEA HD, EYLEA, Dupixent, Libtayo, Biosimilars, Drug Development, Clinical Trials, Regulatory Approval, Patent Litigation, Financial Results, Revenue, Net Income, EPS, Oncology, Ophthalmology, Immunology, Rare Diseases, Corporate Governance, Sanofi, Bayer, Capital Allocation, Dividends, Share Repurchase